Less-toxic chemotherapy boosts NSCLC survival

Increased availability of better systemic chemo and targeted therapies for advanced non-small cell lung cancer (NSCLC) are leading to increased overall survival, according to a 10-year Canadian study.

Researchers from the British Columbia Cancer Agency in Vancouver performed a retrospective chart review of all patients referred to the agency with advanced stage (IIIB or IV) lung cancer and grouped the patients into four one-year time-frame cohorts.

One was termed "baseline" and the other three started six months after each new second-line agent (docetaxel, erlotinib

Latest

Trending